Abstracts tagged "SLE"

Abstract Number: 1310 • 2014 ACR/ARHP Annual Meeting
Predicting Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus Patients at Diagnosis
Maya Gerstein¹, Roberto Ezequiel Borgia², Brian Feldman¹, Deborah M. Levy³, Sharon Sukhdeo⁴, Susanne M. Benseler⁵, Lawrence W.K. Ng¹, Mohamed Abdelhaleem⁶, Earl D. Silverman² and Linda T Hiraki⁷, ¹Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, The Hospital For Sick Children, Toronto, ON, Canada, ⁵Rheumatology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ⁶Department of Paediatric Laboratory Medicine, Division of Haematopathology, The Hospital for Sick Children, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose It can be difficult to differentiate macrophage activation syndrome (MAS) from active pediatric systemic lupus erythematosus (pSLE). However, this differentiation is in determining correct…
Abstract Number: 676 • 2014 ACR/ARHP Annual Meeting
Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register
Emily Sutton¹, Kath D. Watson², David A. Isenberg³, Anisur Rahman⁴, David Jayne⁵, Caroline Gordon⁶, Ben Parker⁷, David P. D'Cruz⁸, Munther A. Khamashta⁹, Pamela Lutalo¹⁰, Peter Lanyon¹¹, Benjamin Rhodes¹², Bridget Griffiths¹³, Edward M. Vital¹⁴, Chee-Seng Yee¹⁵, Christopher Edwards¹⁶, Mohammed Akil¹⁷, Nicola Erb¹⁸, Athiveer Prabu¹⁹, Asad A. Zoma²⁰, Neil McHugh²¹, Hazem Youssef²², Lee-Suan Teh²³, Michael W. Beresford²⁴ and Ian N. Bruce²⁵, ¹University of Manchester, Manchester Academic Health Science Centre, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ³Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Centre for Rheumatology Research, University College London, London, United Kingdom, ⁵Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁶Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Institute of Inflammation and Repair School of Translation Medicine The University of Manchester, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁸Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ⁹Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ¹⁰Peter Gorer Department of Immunobiology, King's College London School of Medicine, London, United Kingdom, ¹¹Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ¹²Rheumatology, Queen Elizabeth Hospital, Birmingham, United Kingdom, ¹³Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ¹⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., United Kingdom, Leeds, United Kingdom, ¹⁵Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, United Kingdom, ¹⁶Tremona Road, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹⁷Rheumatology Department, Sheffield South Yorkshire, United Kingdom, ¹⁸Rheumatology, Russells Hall Hospital, Dudley, United Kingdom, ¹⁹Department of Rheumatology, Worcester Acute Hospitals NHS Trust, Worcester, United Kingdom, ²⁰Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ²¹Rheumatology, Royal National Hospital, Bath, United Kingdom, ²²Department of Rheumatology, NHS Grampian, Aberdeen, United Kingdom, ²³Department of Rhuematology, Royal Blackburn Hospital, Blackburn, United Kingdom, ²⁴Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ²⁵Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Published efficacy data for rituximab in SLE are complex with positive single-centre case series and negative randomised controlled trials. This may be due to…
Abstract Number: 2701 • 2013 ACR/ARHP Annual Meeting
Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus T Cell Signaling
Alexandros P. Grammatikos¹, Debjani Ghosh² and Vasileios C. Kyttaris¹, ¹Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Department of Microbiology and Immunology, The Brody School of Medicine, East Carolina University, Greenville, NC
Background/Purpose: Systemic Lupus Erythematosus (SLE) T cells display an aberrant response to CD3/ TCR stimulation. The CD3/TCR complex in SLE is characterized by the substitution…
Abstract Number: 1639 • 2013 ACR/ARHP Annual Meeting
GWAS In Hispanic and Latin American Individuals Enriched For Amerindian Ancestry Identifies a New Locus Associated With Systemic Lupus Erythematosus
Marta Eugenia Alarcon Riquelme¹, Julie T. Ziegler², Mary E. Comeau³, Elena Sanchez⁴, Bernado Pons-Estel⁵, Eduardo Acevedo⁶, Jorge Mariano Cucho⁶, Ignacio Garcia de la Torre⁷, Mario H. Cardiel⁸, Pedro Miranda⁹, Luis Cattogio¹⁰, Marco Maradiaga¹¹, Jorge Esquivel-Valerio¹², Jose F Moctezuma¹³, Mercedes Garcia¹⁴, Guillermo Berbotto¹⁵, Alejandra Babini¹⁶, Hugo Scherbarth¹⁷, Sergio Toloza¹⁸, Judith A James¹⁹, Teresa Tusie-Luna²⁰, John B Harley²¹, Raphael Zidovetski²², Carl Langefeldt² and Chaim O. Jacob²³, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Wake Forest School of Medicine, Winston-Salem, NC, ³Wake Forest University Health Sciences, Winston-Salem, NC, ⁴King's College London, London, United Kingdom, ⁵Hospital Provincial de Rosario, Rosario, Argentina, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁷Hospital General de Occidente, Zapopan, Mexico, ⁸Centro de Investigacion Clinica de Morelia, Morelia, Mexico, ⁹Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, ¹⁰Hospital Italiano, Buenos Aires, Argentina, ¹¹Hospital General de Culiacán, Culiacan, Sinaloa, Mexico, ¹²Hospital Universitario Dr. José Eleuterio González, Universidad Autonoma de Nuevo León, Nuevo Leon, Mexico, ¹³Hospital General de Mexico, Mexico, Mexico, ¹⁴Hospital San Martin, La Plata, Argentina, ¹⁵Hospital Eva Peron, Granadero Baigorria, Argentina, ¹⁶Hospital Privado de Cordoba, Cordoba, Argentina, ¹⁷H.I.G.A. Oscar E. Alende, Mar del Plata, Argentina, ¹⁸Hospital San Juan Bautista, Catamarca, Argentina, ¹⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁰Instituto de Investigaciones Biomédicas de la Universidad Nacional Autónoma de México, and Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ²¹Childrens Hospital, Cincinnati, OH, ²²University of Southern California, Los Angeles, CA, ²³Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Systemic lupus erythematosus (SLE), a chronic autoimmune disease with a strong genetic component, exhibits a 9:1 female to male ratio and disproportionate impact on…
Abstract Number: 1066 • 2013 ACR/ARHP Annual Meeting
Depression Screening In Patients With Systemic Lupus Erythematosus From The Southeastern United States: Missing Opportunities For Early Diagnosis and Treatment
Cristina Drenkard¹, Charmayne M. Dunlop-Thomas², Gaobin Bao³ and S. Sam Lim⁴, ¹Department of Medicine, Emory University, Atlanta, GA, ²Medicine Rheumatology, Emory University, Atlanta, GA, ³Medicine, Emory University, Atlanta, GA, ⁴Emory University School of Medicine, Division of Rheumatology, Atlanta, GA
Background/Purpose: Depression can be found in 20-60% of SLE patients and has substantial impact on quality of life, disease outcomes and health care costs. Although…
Abstract Number: 610 • 2013 ACR/ARHP Annual Meeting
Disease Specific Quality Of Life Domains Are Impaired In Patients With Lupus Nephritis?
Meenakshi Jolly¹, Zineb Aouhab², Sergio Toloza³, Ana M. Bertoli⁴, Ivana Blazevik⁵, Luis M. Vila⁶, Ioana Moldovan⁷, Karina Marianne D. Torralba⁸, Arif Kaya⁹, Berna Goker¹⁰, Mehmet E. Tezcan¹¹, Seminur Haznedaroglu¹², Josiane Bourré-Tessier¹³, Ann E. Clarke¹⁴, D.J. Wallace¹⁵, Michael H. Weisman¹⁶ and Graciela S. Alarcon¹⁷, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Medicine, John H Stroger Hospital, Chicago, IL, ³Hospital San Juan Bautista, Catamarca, Argentina, ⁴Instituto Reumatológico Strusberg, Cordoba, Cordoba, Argentina, ⁵University of Buenos Aires, Buenos Aries, Argentina, ⁶Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁷Loma Linda Univ Medical Center, Loma Linda, CA, ⁸Rheumatology/Int Med, USC Keck Schl of Medicine, Los Angeles, CA, ⁹Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, ¹⁰Internal Medicine-Rheumatology, Gazi University, Ankara, Turkey, ¹¹Rheumatology, Dr. Lutfi Kirdar Kartal EA Hastanesi, Istanbul, Turkey, ¹²Internal Medicine-Rheumatology, Gazi University School of Medicine, Ankara, Turkey, ¹³Rheumatology, McGill University, Montréal, QC, Canada, ¹⁴Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ¹⁵Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁷Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Often systemic Lupus Erythematosus (SLE) patients with Lupus Nephritis (LN) require frequent visits with their health care providers, follow up, and exposure to immunosuppressive…
Abstract Number: 2703 • 2013 ACR/ARHP Annual Meeting
An Intronic CR2 Polymorphism Associated With Systemic Lupus Erythematosus Alters CTCF Binding and CR1 Expression
Jian Zhao¹, Brendan M. Giles², Rhonda L. Taylor³, Gabriel A. Yette², Kara M. Lough², Lawrence J. Abraham³, Hui Wu⁴, Patrick M. Gaffney⁵, Jennifer A. Kelly⁶, Kenneth M. Kaufman^7,8, John B. Harley^9,10, Carl D. Langefeld¹¹, Elizabeth E. Brown¹², Jeffrey C. Edberg¹³, Robert P. Kimberly¹⁴, Daniela Ulgiati³, Betty P. Tsao¹ and Susan A. Boackle¹⁵, ¹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ²University of Colorado School of Medicine, Aurora, CO, ³University of Western Australia, Perth, Western Australia, Australia, ⁴Rheumatology, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷U.S. Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁸1Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, ⁹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹¹Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ¹²University of Alabama at Birmingham, Birmingham, AL, ¹³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁴Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁵Medicine/Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by the production of antibodies to nuclear antigens, which form immune complexes that deposit in tissues and cause…
Abstract Number: 1607 • 2013 ACR/ARHP Annual Meeting
Two Year Follow-Up On Biologics Use In 13 Centers- Data From The International Registry For Biologics In Systemic Lupus Erythematosus
Ronald F. van Vollenhoven¹, Melinda Mild², Søren Jacobsen³, S. Bernatsky⁴, Daniel J. Wallace⁵, Sang-Cheol Bae⁶, Manuel Ramos-Casals⁷, Francisco J. García-Hernández⁸, R. Ramsey-Goldman⁹, Andrea Doria¹⁰, Marta Mosca¹¹, Michelle A. Petri¹², M Ayala-Gutiérrez¹³, J.G. Hanley¹⁴ and for The SLICC group¹⁵, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, ²Department of medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁴Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁷Laboratorio de Enfermedades Autoinmunes Josep Font, Hospital Clínic, Barcelona, Spain, ⁸Internal Medicine, Hospital Virgen del Rocío, Sevilla, Spain, ⁹Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Rheumatology Unit - Department of Medicine, University of Padova, Padova, Italy, ¹¹Rheumatology Unit, University of Pisa, Pisa, Italy, ¹²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹³Unidad de Enfermedades Autoinmunes, Servicio de Medicina Interna, Hospital Carlos Haya, Malaga, Spain, ¹⁴Division of Rheumatology, Halifax, NS, Canada, ¹⁵Department of Medicine, the Karolinska Institute, Stockholm, Sweden
Background/Purpose: Only one biologic agent has been approved for use in SLE, but some are used off-label in various settings. To obtain systematic information regarding…
Abstract Number: 1070 • 2013 ACR/ARHP Annual Meeting
Characteristics and Medication Use Patterns Among Belimumab Users In a Commercially Insured Population With Systemic Lupus Erythematosus
Xuehua Ke¹, Jeetvan Patel², Hong Kan², Debra F Eisenberg¹ and Alan Oglesby², ¹HealthCore Inc, Wilmington, DE, ²GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Belimumab is a B lymphocyte stimulator-specific inhibitor approved for treatment of systemic lupus erythematosus (SLE). The purpose of the study was to describe medication…
Abstract Number: 562 • 2013 ACR/ARHP Annual Meeting
The Knock-Out Of TWEAK Receptor/Fn14 Ameliorates Lupus Nephritis In MRL/Lpr Mice
Yumin Xia¹, Leal Herlitz², Simona Gindea¹, Jing Wen¹, Rahul Pawar¹, Alexander Misharin³, Harris R. Perlman⁴, Ping Wu⁵, Jennifer Michaelson⁵, Linda Burkly⁵ and Chaim Putterman⁶, ¹Albert Einstein College of Medicine, Bronx, NY, ²The Department of Pathology, Columbia University Medical Center, New York, NY, ³Medicine, Division of Rheumatology, Northwestern University, Chicago, IL, ⁴Northwestern University, Chicago, IL, ⁵Biogen Idec, Cambridge, MA, ⁶The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Renal mesangial cells, podocytes, and tubular cells express Fn14, the sole confirmed receptor for the tumor necrosis factor (TNF)-family member cytokine TWEAK (TNF-like weak…
Abstract Number: 2674 • 2013 ACR/ARHP Annual Meeting
Vitamin D Deficiency Is Common and Associated With Increased C-Reactive Protein In Children With Lupus: An Atherosclerosis Prevention In Pediatric Lupus Erythematosus Substudy
Angela B. Robinson¹, Vin Tangpricha², Eric Yow³, Reut Gurion⁴, Grace McComsey⁴ and Laura E. Schanberg⁵, ¹Pediatric Infectious Disease, Rheumatology and Geographic Medicine, Rainbow Babies and Children's Hospital / Case Medical Center, Cleveland, OH, ²Medicine, Emory University School of Medicine, Atlanta, GA, ³Biostatistics, Duke Clinical Research Institute, Durham, NC, ⁴Pediatric Infectious Diseases, Rheumatology, and Geographic Medicine, Rainbow Babies and Children's Hospital / Case Medical Center, Cleveland, OH, ⁵Pediatrics, Duke University Medical Center, Durham, NC
Background/Purpose: Epidemiologic associations suggest vitamin D may play a role in inflammation and progression of atherosclerosis. Using frozen serum, carotid intima medial thickness (CIMT) measurements,…
Abstract Number: 1611 • 2013 ACR/ARHP Annual Meeting
Off-Label Use Of Rituximab For Systemic Lupus Erythematosus in Europe: Limited Use Mostly In Refractory Patients
Ronald F. van Vollenhoven¹, Melinda Mild², Andrea Doria³, T. Dörner⁴, Gianfranco Ferraccioli⁵, Frederic Houssiau⁶, T.W.J. Huizinga⁷, David A. Isenberg⁸, László Kovács⁹, Guillermo Ruiz-Irastorza¹⁰, Danilo Squatrito¹¹, Alexandre Voskuyl¹², Marta Mosca¹³, G D Sebastiani¹⁴, Murat Inanç¹⁵, Gabriella Szücs¹⁶, Søren Jacobsen¹⁷, A. Castro¹⁸ and for The IRBIS-EMA group¹⁹, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, ²Department of medicine, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit - Department of Medicine, University of Padova, Padova, Italy, ⁴Charité University Medicine Berlin, Berlin, Germany, ⁵Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ⁶Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁹Department of Rheumatology, University of Szeged, Szeged, Hungary, ¹⁰Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, ¹¹Center for Autoimmune Diseases, Department of Internal Medicine, Careggi Hospital- Florence, Florence, Italy, ¹²Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ¹³Rheumatology Unit, University of Pisa, Pisa, Italy, ¹⁴Rheumatology Unit, San Camillo-Forlanini Hospital, Rome, Rome, Italy, ¹⁵Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ¹⁶Department of Rheumatology, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary, ¹⁷Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ¹⁸Hospital Universitari de Reus, Spain, Reus, Spain, ¹⁹ClinTRID, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Rituximab (Rituxan, Mabthera; RTX) has not been approved for use in SLE, but uncontrolled observations have suggested efficacy in some patients and the medication…
Abstract Number: 1039 • 2013 ACR/ARHP Annual Meeting
Risk Of High-Grade Cervical Dysplasia In Women With Systemic Inflammatory Diseases
Seoyoung C. Kim¹, Robert J. Glynn², Edward Giovannucci³, Sonia Hernandez-diaz⁴, Jun Liu⁵, Sarah Feldman², Elizabeth W. Karlson⁶, Sebastian Schneeweiss⁷ and Daniel H. Solomon^8,9, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard School of Publich Health, Boston, MA, ⁴Harvard School of Public Health, Boston, MA, ⁵Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁷Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁸Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁹Division of Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Human papillomaviruses (HPV) are causes of high-grade cervical dysplasia and cervical cancer. Persistent HPV infection, the major risk factor for cervical cancer, is associated…
Abstract Number: 571 • 2013 ACR/ARHP Annual Meeting
Protective Effect Of Inducible Adeno-Associated Virus Mediated IL-2 Gene Therapy On Tissue Damages In Lupus-Prone Mice
Masayuki Mizui¹, Tomohiro Koga², Linda Lieberman³, Jessica Beltran³, Mark C. Johnson⁴, José C. Crispin², Roland Tisch⁴ and George C. Tsokos⁵, ¹Division of Rheumatology, Department of Medicine,, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose: IL-2 plays critical roles not only in immune responses but also in peripheral tolerance. Impairment of IL-2 production has been linked to the development…
Abstract Number: 2554 • 2013 ACR/ARHP Annual Meeting
In Vitro Fertilization In Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Series Of 82 Cycles
Pauline Orquevaux¹, Agathe Masseau², Véronique le Guern³, Vanessa Gayet⁴, Danièle Vauthier-Brouzes⁵, Du Boutin⁶, Bertrand Wechsler⁷, Nathalie Morel⁸, Jean Loup Pennaforte¹, Jean-Charles Piette⁹ and Nathalie Costedoat-Chalumeau¹⁰, ¹Hu Robert Debre, CHU Reims, Reims, France, ²Internal Medicine Department, Nantes University Hospital, Nantes, France, ³Department of Internal Medicine, Hôpital Cochin, Paris, France, ⁴Cochin Hospital, Paris, France, ⁵gynecology obstetrical, Pitié Salpétrière Hospital, Paris, France, ⁶Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁷Internal Medicine, DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ⁸Internal Medicine, COCHIN, Paris, France, ⁹Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France, ¹⁰Internal Medicine, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) undergoing in vitro fertilization (IVF) are at increased risk of both hormone-associated flare and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].